Views and Perspectives of Cutaneous Squamous Cell Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 16152
Special Issue Editors
Interests: skin carcinogenesis; cancer immune surveillance; chronic skin inflammation; oncogenic virus; sexually transmitted infections
Interests: immuno-dermatology; infectious skin diseases / sexually transmitted infections; non-melanoma skin cancer (NMSC); skin disease(s) following organ transplantation; identification of clinical, genetic and immunosuppressive factors predisposing to NMSC in immunosuppressed; tumour markers for cutaneous squamous cell carcinoma
Special Issue Information
Dear Colleagues,
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer after basal cell carcinoma and represents about 20% of nonmelanoma skin cancer. Most cSCCs are treated successfully by surgical excision and have a good prognosis, but about 10% of these cancers show a more aggressive behavior. These cases of locally advanced and metastatic cSCC are associated with a high mortality rate. They are not amenable to local surgery or radiotherapy and require systemic therapy. In many countries, the incidence of cSCC is rising, and due to increasing sun exposure, outdoor leisure activities and life expectancy numbers are expected to increase further in the future, representing growing challenges for treatment and prevention.
In this Special Issue, we aim to compile papers addressing the importance of cSCC in public health regarding epidemiological aspects, prevention, and medical care. We are pleased to invite you to submit original research studies or reviews outlining future demands of cSCC management, which may also include your personal views and opinions. Research areas may include (but are not limited to) the following: epidemiology, risk factors, precancerous lesions, oncogenic mechanisms, diagnosis, and strategies for treatment and prevention of cSCC.
We look forward to receiving your contributions.
Dr. Thomas Meyer
Dr. Alexandra Geusau
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- actinic keratosis
- Morbus Bowen
- UV exposure
- immunosuppression
- advanced cSCC
- metastatic cSCC
- cancer progression
- cancer biomarker
- immunotherapy
- cancer prevention